We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$710M
AUM Growth
-$45.7M
Cap. Flow
-$39.7M
Cap. Flow %
-5.59%
Top 10 Hldgs %
9.53%
Holding
2,469
New
584
Increased
596
Reduced
458
Closed
638

Sector Composition

Rank Sector Weight
1 Technology 11.11%
2 Energy 9.76%
3 Consumer Discretionary 8.51%
4 Industrials 8.43%
5 Healthcare 7.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SRGA
1651
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$29K ﹤0.01%
+203
New +$29.4K
STV
1652
DELISTED
China Digital Tv Hldgs Co Ltd
STV
$29K ﹤0.01%
+8,030
New +$30.3K
VVUS
1653
DELISTED
Vivus Inc
VVUS
$29K ﹤0.01%
+760
New +$33.9K
ENOV icon
1654
Enovis
ENOV
$1.53B
$28K ﹤0.01%
+291
New +$32.7K
IRMD icon
1655
iRadimed
IRMD
$1.18B
$28K ﹤0.01%
+4,000
New +$36.2K
LGND icon
1656
Ligand Pharmaceuticals
LGND
$6.36B
$28K ﹤0.01%
962
-9,618
-91% -$319K
RDNT icon
1657
RadNet
RDNT
$5.69B
$28K ﹤0.01%
+4,160
New +$26.9K
ETFC
1658
DELISTED
E*Trade Financial Corporation
ETFC
$28K ﹤0.01%
1,260
-1,865
-60% -$40.9K
NWY
1659
DELISTED
New York & Co Inc
NWY
$28K ﹤0.01%
9,100
-1,600
-15% -$5.4K
CHMT
1660
DELISTED
Chemtura Corporation
CHMT
$28K ﹤0.01%
+1,200
New +$29.7K
RPRX
1661
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$28K ﹤0.01%
+2,800
New +$41.5K
ALNT icon
1662
Allient
ALNT
$1.92B
$27K ﹤0.01%
2,850
-5,400
-65% -$51.6K
AMD icon
1663
Advanced Micro Devices
AMD
$789B
$27K ﹤0.01%
+7,840
New +$31.7K
AUB icon
1664
Atlantic Union Bankshares
AUB
$5.97B
$27K ﹤0.01%
+1,150
New +$27.8K
DWSN icon
1665
Dawson Geophysical
DWSN
$135M
$27K ﹤0.01%
2,485
+1,225
+97% +$14.7K
MXL icon
1666
MaxLinear
MXL
$6.8B
$27K ﹤0.01%
3,900
TCRT icon
1667
Alaunos Therapeutics
TCRT
$4.86M
$27K ﹤0.01%
+68
New +$32.8K
INFN
1668
DELISTED
Infinera Corporation Common Stock
INFN
$27K ﹤0.01%
2,530
-22,270
-90% -$218K
BBRG
1669
DELISTED
Bravo Brio Restaurant Group Inc.
BBRG
$27K ﹤0.01%
2,100
+1,100
+110% +$16K
LINE
1670
DELISTED
LINN ENERGY LLC COM UTS REP LTD LIABILITY CO INTS
LINE
$27K ﹤0.01%
910
-14,090
-94% -$439K
AGYS icon
1671
Agilysys
AGYS
$3.06B
$26K ﹤0.01%
2,200
+700
+47% +$8.97K
CCEP icon
1672
Coca-Cola Europacific Partners
CCEP
$47.9B
$26K ﹤0.01%
575
-4,570
-89% -$214K
CLF icon
1673
Cleveland-Cliffs
CLF
$6.99B
$26K ﹤0.01%
2,500
-1,490
-37% -$22.8K
MFIC icon
1674
MidCap Financial Investment
MFIC
$804M
$26K ﹤0.01%
+1,067
New +$27.6K
NRT
1675
North European Oil Royalty Trust
NRT
$81M
$26K ﹤0.01%
1,250

Similar funds

Prelude Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Prelude Capital Management held 2,469 positions worth $710M, down 6% from $756M the previous quarter. Its ten largest holdings account for 9.5% of the portfolio.

Prelude Capital Management withdrew a net $39.7M in Q3 2014, closing 638 positions and reducing 458 holdings. Its most notable exit was FOREST LABORATORIES INC, an estimated $5.64M position sold in full.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 9.1% a quarter earlier, followed by Energy and Consumer Discretionary.

Against the trend, Prelude Capital Management opened a new position in CONCUR TECHNOLOGIES INC worth $6.4M.

  • Prelude Capital Management's largest Q3 2014 buy was CONCUR TECHNOLOGIES INC: 50,447 shares worth $6.4M.
  • Prelude Capital Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q3 2014, an estimated $6.42M increase.
  • Prelude Capital Management's biggest Q3 2014 reduction was Liberty Interactive Corporation Series A Liberty Ventures, cutting an estimated $4.48M.
  • Prelude Capital Management fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $5.64M.
  • Prelude Capital Management's ten largest holdings make up 9.5% of its $710M portfolio in Q3 2014.
  • Prelude Capital Management opened 584 new positions and closed 638 in Q3 2014.
  • Prelude Capital Management's portfolio value fell 6% quarter-over-quarter to $710M.

Based on Prelude Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.